Oncolytics Biotech Adds Leading GI Oncologists to Advisory Board as It Prepares Pivotal Pelareorep Trials

Oncolytics Biotech ( (ONCY) ) has provided an announcement.

On January 7, 2026, Oncolytics Biotech expanded its Gastrointestinal Tumor Scientific Advisory Board by appointing three high-profile gastrointestinal oncology experts—Drs. Eileen O’Reilly and Neil Segal of Memorial Sloan Kettering Cancer Center and Dr. Van Morris of MD Anderson Cancer Center—to help guide the late-stage clinical and strategic development of pelareorep as a platform immunotherapy across pancreatic, colorectal, and anal cancers. With the GI advisory board now comprising six global leaders, the company is reinforcing its clinical and strategic infrastructure as it prepares registration-enabling trials in these high-value indications, underpinned by earlier clinical data suggesting improved survival and response rates versus historical benchmarks in first-line pancreatic cancer, squamous cell anal carcinoma, and KRAS-mutant metastatic colorectal cancer—positioning Oncolytics to potentially enhance its competitive standing in GI oncology and attract greater attention from larger pharmaceutical players.

The most recent analyst rating on (ONCY) stock is a Hold with a $0.87 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.

Spark’s Take on ONCY Stock

According to Spark, TipRanks’ AI Analyst, ONCY is a Neutral.

The score is driven primarily by weak financial performance (no revenue, large losses, heavy cash burn) and heightened balance-sheet strain from sharply reduced equity. Technical indicators also point to a weak trend and bearish momentum. Valuation provides only limited support because the negative P/E reflects ongoing losses and there is no dividend yield provided.

To see Spark’s full report on ONCY stock, click here.

More about Oncolytics Biotech

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent designed to convert immunologically “cold” tumors into “hot” ones by activating innate and adaptive immune responses. The company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors across metastatic pancreatic and breast cancers—both of which have received Fast Track designation from the U.S. FDA—as well as other gastrointestinal tumors, and is actively seeking strategic partnerships to accelerate development and commercial impact.

Average Trading Volume: 760,008

Technical Sentiment Signal: Sell

Current Market Cap: $103.8M

For an in-depth examination of ONCY stock, go to TipRanks’ Overview page.